Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Ballard

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2016
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases ActivityPeter Ballard, James W T Yates, Zhenfan Yang, et al.
Bioorganic & Medicinal Chemistry Letters|July 26, 2011
Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancerRobert H Bradbury, Neil J Hales, Alfred A Rabow, et al.
Bioorganic & Medicinal Chemistry Letters|September 18, 2007
Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinasePeter Ballard, Bernard C Barlaam, Robert H Bradbury, et al.
Bioorganic & Medicinal Chemistry Letters|December 7, 2007
A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinaseBernard Barlaam, Peter Ballard, Robert H Bradbury, et al.
Journal of Medicinal Chemistry|February 12, 2013
Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinasesMatt Addie, Peter Ballard, David Buttar, et al.
Cancer Discovery|June 5, 2014
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancerDarren A E Cross, Susan E Ashton, Serban Ghiorghiu, et al.
Cancer Research|March 30, 2016
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical ModelsHazel M Weir, Robert H Bradbury, Mandy Lawson, et al.
Journal of Medicinal Chemistry|September 26, 2015
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and AntagonistChris De Savi, Robert H Bradbury, Alfred A Rabow, et al.
Journal of Medicinal Chemistry|October 2, 2014
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptorM Raymond V Finlay, Mark Anderton, Susan Ashton, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2016
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases ActivityPeter Ballard, James W T Yates, Zhenfan Yang, et al.
Bioorganic & Medicinal Chemistry Letters|July 26, 2011
Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancerRobert H Bradbury, Neil J Hales, Alfred A Rabow, et al.
Bioorganic & Medicinal Chemistry Letters|September 18, 2007
Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinasePeter Ballard, Bernard C Barlaam, Robert H Bradbury, et al.
Bioorganic & Medicinal Chemistry Letters|December 7, 2007
A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinaseBernard Barlaam, Peter Ballard, Robert H Bradbury, et al.
Journal of Medicinal Chemistry|February 12, 2013
Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinasesMatt Addie, Peter Ballard, David Buttar, et al.
Cancer Discovery|June 5, 2014
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancerDarren A E Cross, Susan E Ashton, Serban Ghiorghiu, et al.
Cancer Research|March 30, 2016
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical ModelsHazel M Weir, Robert H Bradbury, Mandy Lawson, et al.
Journal of Medicinal Chemistry|September 26, 2015
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and AntagonistChris De Savi, Robert H Bradbury, Alfred A Rabow, et al.
Journal of Medicinal Chemistry|October 2, 2014
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptorM Raymond V Finlay, Mark Anderton, Susan Ashton, et al.
Pageof 3